Mississippi saw a 55 percent increase in drug overdose deaths from 2019 to 2020. Opioids - such as prescription pain relievers, heroin, and illegally manufactured synthetic opioids such as fentanyl - are the main driver of overdose deaths. This statistic shows the percent change in drug overdose deaths in the U.S. from 2019 to 2020, by state.

In 2023, around 72,776 people in the United States died from a drug overdose that involved fentanyl. This was the second-highest number of fentanyl overdose deaths ever recorded in the United States, and a significant increase from the number of deaths reported in 2019. Fentanyl overdoses are now the driving force behind the opioid epidemic, accounting for the majority of overdose deaths in the United States. What is fentanyl? Fentanyl is an extremely potent synthetic opioid similar to morphine, but more powerful. It is a prescription drug but is also manufactured illegally and is sometimes mixed with other illicit drugs such as heroin and cocaine, often without the user’s knowledge. The potency of fentanyl makes it very addictive and puts users at a high risk for overdose. Illegally manufactured fentanyl has become more prevalent in the United States in recent years, leading to a huge increase in drug overdose deaths. In 2022, the rate of drug overdose death involving fentanyl was 22.7 per 100,000 population, compared to a rate of just one per 100,000 population in the year 2013. Fentanyl overdoses by gender and race/ethnicity As of 2022, the rate of drug overdose deaths involving fentanyl in the United States is over two times higher among men than women. Rates of overdose death involving fentanyl were low for both men and women until around the year 2014 when they began to quickly increase, especially for men. In 2022, there were around 19,880 drug overdose deaths among women that involved fentanyl compared to 53,958 such deaths among men. At that time, the rate of fentanyl overdose deaths was highest among non-Hispanic American Indian or Alaska Natives and lowest among non-Hispanic Asians. However, from the years 2014 to 2018, non-Hispanic whites had the highest fentanyl overdose death rates.

ObjectiveU.S. drug-related overdose deaths and Emergency Department (ED) visits rose in 2020 and again in 2021. Many academic studies and the news media attributed this rise primarily to increased drug use resulting from the societal disruptions related to the coronavirus (COVID-19) pandemic. A competing explanation is that higher overdose deaths and ED visits may have reflected a continuation of pre-pandemic trends in synthetic-opioid deaths, which began to rise in mid-2019. We assess the evidence on whether increases in overdose deaths and ED visits are likely to be related primarily to the COVID-19 pandemic, increased synthetic-opioid use, or some of both.MethodsWe use national data from the Centers for Disease Control and Prevention (CDC) on rolling 12-month drug-related deaths (2015–2021); CDC data on monthly ED visits (2019-September 2020) for EDs in 42 states; and ED visit data for 181 EDs in 24 states staffed by a national ED physician staffing group (January 2016-June 2022). We study drug overdose deaths per 100,000 persons during the pandemic period, and ED visits for drug overdoses, in both cases compared to predicted levels based on pre-pandemic trends.ResultsMortality. National overdose mortality increased from 21/100,000 in 2019 to 26/100,000 in 2020 and 30/100,000 in 2021. The rise in mortality began in mid-to-late half of 2019, and the 2020 increase is well-predicted by models that extrapolate pre-pandemic trends for rolling 12-month mortality to the pandemic period. Placebo analyses (which assume the pandemic started earlier or later than March 2020) do not provide evidence for a change in trend in or soon after March 2020. State-level analyses of actual mortality, relative to mortality predicted based on pre-pandemic trends, show no consistent pattern. The state-level results support state heterogeneity in overdose mortality trends, and do not support the pandemic being a major driver of overdose mortality.ED visits. ED overdose visits rose during our sample period, reflecting a worsening opioid epidemic, but rose at similar rates during the pre-pandemic and pandemic periods.ConclusionThe reasons for rising overdose mortality in 2020 and 2021 cannot be definitely determined. We lack a control group and thus cannot assess causation. However, the observed increases can be largely explained by a continuation of pre-pandemic trends toward rising synthetic-opioid deaths, principally fentanyl, that began in mid-to-late 2019. We do not find evidence supporting the pandemic as a major driver of rising mortality. Policymakers need to directly address the synthetic opioid epidemic, and not expect a respite as the pandemic recedes.

This data visualization presents county-level provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. County-level provisional counts include deaths occurring within the 50 states and the District of Columbia, as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts (see Technical Notes). The provisional data presented on the dashboard below include reported 12 month-ending provisional counts of death due to drug overdose by the decedent’s county of residence and the month in which death occurred. Percentages of deaths with a cause of death pending further investigation and a note on historical completeness (e.g. if the percent completeness was under 90% after 6 months) are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts (see Technical Notes). Counts between 1-9 are suppressed in accordance with NCHS confidentiality standards. Provisional data presented on this page will be updated on a quarterly basis as additional records are received. Technical Notes Nature and Sources of Data Provisional drug overdose death counts are based on death records received and processed by the National Center for Health Statistics (NCHS) as of a specified cutoff date. The cutoff date is generally the first Sunday of each month. National provisional estimates include deaths occurring within the 50 states and the District of Columbia. NCHS receives the death records from the state vital registration offices through the Vital Statistics Cooperative Program (VSCP). The timeliness of provisional mortality surveillance data in the National Vital Statistics System (NVSS) database varies by cause of death and jurisdiction in which the death occurred. The lag time (i.e., the time between when the death occurred and when the data are available for analysis) is longer for drug overdose deaths compared with other causes of death due to the time often needed to investigate these deaths (1). Thus, provisional estimates of drug overdose deaths are reported 6 months after the date of death. Provisional death counts presented in this data visualization are for “12 month-ending periods,” defined as the number of deaths occurring in the 12 month period ending in the month indicated. For example, the 12 month-ending period in June 2020 would include deaths occurring from July 1, 2019 through June 30, 2020. The 12 month-ending period counts include all seasons of the year and are insensitive to reporting variations by seasonality. These provisional counts of drug overdose deaths and related data quality metrics are provided for public health surveillance and monitoring of emerging trends. Provisional drug overdose death data are often incomplete, and the degree of completeness varies by jurisdiction and 12 month-ending period. Consequently, the numbers of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Cause of Death Classification and Definition of Drug Deaths Mortality statistics are compiled in accordance with the World Health Organizations (WHO) regulations specifying that WHO member nations classify and code causes of death with the current revision of the International Statistical Classification of Diseases and Related Health Problems (ICD). ICD provides the basic guidance used in virtually all countries to code and classify causes of death. It provides not only disease, injury, and poisoning categories but also the rules used to select the single underlying cause of death for tabulation from the several diagnoses that may be reported on a single death certificate, as well as definitions, tabulation lists, the format of the death certificate, and regul

It is projected that if the opioid overdose crisis stabilizes by the year 2020 there will be around ******* overdose deaths from prescription and illicit opioids from 2016 to 2025. If the crisis does not stabilize until the year 2025 it is predicted that overdose deaths due to illicit opioids will reach a total of over ****million from 2016 to 2025.

ObjectiveU.S. drug-related overdose deaths and Emergency Department (ED) visits rose in 2020 and again in 2021. Many academic studies and the news media attributed this rise primarily to increased drug use resulting from the societal disruptions related to the coronavirus (COVID-19) pandemic. A competing explanation is that higher overdose deaths and ED visits may have reflected a continuation of pre-pandemic trends in synthetic-opioid deaths, which began to rise in mid-2019. We assess the evidence on whether increases in overdose deaths and ED visits are likely to be related primarily to the COVID-19 pandemic, increased synthetic-opioid use, or some of both.MethodsWe use national data from the Centers for Disease Control and Prevention (CDC) on rolling 12-month drug-related deaths (2015–2021); CDC data on monthly ED visits (2019-September 2020) for EDs in 42 states; and ED visit data for 181 EDs in 24 states staffed by a national ED physician staffing group (January 2016-June 2022). We study drug overdose deaths per 100,000 persons during the pandemic period, and ED visits for drug overdoses, in both cases compared to predicted levels based on pre-pandemic trends.ResultsMortality. National overdose mortality increased from 21/100,000 in 2019 to 26/100,000 in 2020 and 30/100,000 in 2021. The rise in mortality began in mid-to-late half of 2019, and the 2020 increase is well-predicted by models that extrapolate pre-pandemic trends for rolling 12-month mortality to the pandemic period. Placebo analyses (which assume the pandemic started earlier or later than March 2020) do not provide evidence for a change in trend in or soon after March 2020. State-level analyses of actual mortality, relative to mortality predicted based on pre-pandemic trends, show no consistent pattern. The state-level results support state heterogeneity in overdose mortality trends, and do not support the pandemic being a major driver of overdose mortality.ED visits. ED overdose visits rose during our sample period, reflecting a worsening opioid epidemic, but rose at similar rates during the pre-pandemic and pandemic periods.ConclusionThe reasons for rising overdose mortality in 2020 and 2021 cannot be definitely determined. We lack a control group and thus cannot assess causation. However, the observed increases can be largely explained by a continuation of pre-pandemic trends toward rising synthetic-opioid deaths, principally fentanyl, that began in mid-to-late 2019. We do not find evidence supporting the pandemic as a major driver of rising mortality. Policymakers need to directly address the synthetic opioid epidemic, and not expect a respite as the pandemic recedes.

The drug overdose death rate among women aged 65 to 74 in the United States in 2020 was *** per 100,000 population. Synthetic opioids such as fentanyl are the leading cause of drug overdose death in the United States. This statistics shows the drug overdose death rate for women aged 65 to 74 in the United States in 2019 and 2020, by race/ethnicity.

In 2022, the age-adjusted drug overdose death rate in the United States was **** per 100,000 population. Opioids are the main driver of overdose deaths in the United States. This statistic presents the age-adjusted drug overdose death rate in the U.S. from 1999 to 2022, per 100,000 population.

Left hand columns: CDC data from 42 states for ratio of non-fatal drug-related ED visits in Jan.-Sept. 2020. Table shows ratio of visits during 2020 to visits during same month in 2019. Right hand columns: Data from ED staffing company on drug-related ED visits to 181 EDs in 24 states over January 2017-June 2022. Table shows average for indicated periods of monthly ratios of visits in January 2017-February 2020 to visits in the same months a year earlier and March-December 2020 and January 2021-June 2022 to visits in the same months in 2019. Ratios are computed at the ED level and then averaged across EDs within each month. 95% confidence intervals are reported in brackets. Last row shows average ratio of opioid/related ED visits to all overdose visits for the months in the indicated period.

National provisional drug overdose deaths by month and 2013 NCHS Urban–Rural Classification Scheme for Counties. Drug overdose deaths are identified using underlying cause-of-death codes from the Tenth Revision of ICD (ICD–10): X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). Deaths are based on the county of residence in the United States. Death counts provided are for “12-month ending periods,” defined as the number of deaths occurring in the 12-month period ending in the month indicated. Estimates for 2020 are based on provisional data. Estimates for 2018 and 2019 are based on final data. For more information on NCHS urban-rural classification, see: https://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf

Deaths as a result of drug overdoses in Portugal amounted to ** in 2019, which is the second highest number of annual deaths reported in the provided time interval. In 2011, drug deaths fell to only **, before reaching ** just four years later. In 2020, drug-induced deaths were counted at **. In 2021, there were ** deaths by overdose, the highest value recorded. Low death rate compared to Europe When compared with the rest of Europe, Portugal has a fairly low incidence of drug deaths. A rate of ** drug deaths per million population (pmp) means that Portugal only had a higher drug death rate than a few countries in the continent, and a significantly lower rate than the ** deaths pmp in Norway, which is the highest in Europe. In 2001, Portugal became the first country in the world to decriminalize the consumption of drugs. The low amount of drug deaths in Portugal is usually attributed to this policy of decriminalization. Breakdown of drugs consumed The class of drugs that caused the highest share of individuals seeking treatment in Portugal, in 2021, were cannabis, with approximately ** percent of Portuguese drug treatment entrants seeking treatment primarily due to the use of this drug class. With a slightly lower share, opioids caused **** percent of drug treatment entries in Portugal. In 2022, Portugal had approximately ****** individuals in opioid substitution treatment, which was the sixth-highest in Europe.

The drug overdose death rate among men aged 65 to 74 in the United States in 2020 was 19.2 per 100,000 population. Synthetic opioids such as fentanyl are the leading cause of drug overdose death in the United States. This statistics shows the drug overdose death rate for men aged 65 to 74 in the United States in 2019 and 2020, by race/ethnicity.

Title: Prevalence of hepatitis C virus among fatal drug overdoses in Tennessee: an analysis using 2019–2020 Tennessee State Unintentional Drug Overdose Reporting System Data Authors: Jessica Korona-Bailey, Sarah Riley Saint, Lindsey Sizemore, Heather Wingate, Paula Shoup, Amy Hawes, and Sutapa Mukhopadhyay CEDEP Program: VH Product type: publication Conference, meeting, or publication accepted to: Annals of Epidemiology

Corresponding with the opioid crisis in Canada, there has been a notable increase in the number of overdose incidents in federal custody (McKendy et al., 2020). As part of ongoing tracking efforts, the current study provides an overview of non-fatal overdose incidents in federal institutions in 2019/2020.

According to Cognitive Market Research, the Global Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

  The global opioid market will expand significantly by XX% CAGR between 2024 and 2030.
  The Pain Relief segment accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
  The hospital pharmacies had a market share of about XX% in 2023.
  The Extended Release /Long-Acting Opioids holds the largest share and is expected to grow in the coming years as well.
  The injectable segment is the market's largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
  The oxycodone segment holds the largest share and is expected to grow in the coming years as well.
  North America region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.

Market Dynamics of the Opioids

Rising prevalence of chronic pain conditions globally

The increased prescription of painkillers during post-operative procedures and an increase in patients with terminally chronic pain or diseases including HIV, and severe cough brought on by lung infections are two causes that are anticipated to increase opioid use as a pain reliever. Chronic pain affects an estimated 20% of the global population, with conditions such as arthritis, cancer, and lower back pain contributing to the growing demand for effective pain management solutions. In the past, it resulted in a demand surge for opioids and boosted growth. Another factor for the growth of the opioid drug market is the spike in the number of surgeries. According to the National Health Interview Survey (NHIS) conducted by the Centers for Disease Control and Prevention (CDC) in 2019, the prevalence of high-impact chronic pain in the United States was 7.4 percent.

(Source-https://www.cdc.gov/nchs/data/databriefs/db390-H.pdf)

The aging population’s vulnerability is at high risk of chronic diseases such as cardiovascular diseases, arthritis, and cancer due to the high comorbid conditions. Declining fertility and mortality rates are some factors contributing to the geriatric population's rise. The impact of chronic pain increases with age and is highest among adults aged 65 years and above. Therefore, the rising geriatric population is anticipated to increase the demand for opioid drugs to manage chronic pain. According to the World Health Organization (WHO), the geriatric population increased from 1.0 million in 2020 to 1.4 million in 2021.

(Source-https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)

Opioid addiction and its side effects pose significant challenges to the market

One of the major challenges for this market is the high potential for abuse and addiction, physicians have scaled back their pain management prescriptions, decreasing global scales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers. The patient may become tolerant and need more and more drugs to achieve the effect of smoothing the pain. Moreover, using opioids for an extended period can develop a dependency, and after leaving the drug, the patient may suffer from withdrawal symptoms such as anxiety, irritability, drug cravings, tremors (shaking), and others. The heightened regulatory scrutiny has resulted in stricter guidelines for prescribing opioids, impacting accessibility for patients in genuine need of pain relief. Regulatory changes often aim to strike a balance between ensuring access for patients and preventing misuse. The forecasted period illustrates a decrease in the opioid market growth due to the adversities and the negative effects of opioids. Researchers and experts have considered this and are making constant efforts to reduce and minimize the negative side effects of opioids. As per the record, drug overdose in the year 2018, had 657 deaths.

(Source-https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-august-2018/download)

Furthermore, the Millennium Health's Signals report (2020) revealed that there was a rise in non-prescribe...

During 2023, there were a total of 8,606 deaths from opioid overdose in Canada, 2,648 of which occurred in the province of Ontario. This statistic shows the number of deaths from opioid overdose in Canada in 2023, by province. Opioid Use and Misuse Opioids are commonly prescribed as both short-term and long-term pain management strategies. Unfortunately, opioids are sometimes used problematically, including taking increased amounts, tampering with the route of administration, or using with the goal to improve mood, all of which can lead to addiction, overdose, and even death. In 2023, there were around 6,462 hospitalizations in Canada due to opioid poisoning. Opioid Crisis in Canada Among Canadian adults, the majority view the opioid issues of the country as a serious problem or a crisis. Moreover, many opioid deaths also involve the use of a stimulant, which adds to the polysubstance nature of the opioid crisis. Efforts against the opioid crisis in Canada are multi-faceted. One way is focused on reducing possible harm from using illicit opioid sources such as heroin or other street opioids through the use of opioid agonist treatment methods including methadone and naloxone.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Number of deaths and age-specific mortality rates for selected grouped causes, by age group and sex, 2000 to most recent year.

"Using ED data to track trends in nonfatal drug overdoses is a critical strategy for expanding overdose surveillance and tailoring prevention resources to populations most affected, including initiation of medication-assisted treatment in ED settings and subsequent linkage to care for substance use disorders." - Nonfatal Drug Overdoses Treated in Emergency Departments — United States, 2016–2017, CDC MMWR Weekly / April 3, 2020 / 69(13);371–376 - https://www.cdc.gov/mmwr/volumes/69/wr/mm6913a3.htmNotes:As of April 2019, this map contains the most recent data available at the sub-county level for deaths (2012-2016), hospitalizations (2012-2015) and emergency room visits (2011-2015).All data comes from the New Mexico Department of Health Indicator Based Information System (NM-IBIS)Click on individual map layer items below ("Layers") for information about sources and methods for each data set.For Hospitalization and Emergency Room data, three NM hospitals do not report: 2 Indian Health Service Hospitals in northwestern New Mexico, and the Veteran's Administration Hospital in Albuquerque.

The rate of 911 calls to police for overdoses per 1,000 residents in an area. Since the data comes from 911 calls, it is possible that multiple calls could be made for a single incident. Source: Baltimore City Police Department Years Available: 2018, 2019, 2020, 2021, 2022, 2023